RGEN
Repligen Corporation · Healthcare · Medical - Instruments & Supplies
Señales de momentum (gestores comparables):
amplitud de titulares +10.5% ·
flujo de acciones -4.9% ·
nuevas posiciones netas +4.8%
· fórmula
Fragmentación de la titularidad: más titulares, participación agregada más pequeña
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 125 | +9 | 40.15M | $5.47B | +16 | −8 |
| Q1 2026 | 120 | -2 | 41.26M | $4.90B | +8 | −11 |
| Q4 2025 | 122 | -3 | 43.70M | $7.16B | +1 | −3 |
| Q3 2025 | 21 | +2 | 26.22M | $3.51B | +3 | −2 |
| Q2 2025 | 17 | +1 | 26.68M | $3.32B | +2 | −1 |
| Q1 2025 | 13 | +1 | 13.27M | $1.69B | +1 | n/a |
| Q4 2024 | 12 | 0 | 12.86M | $1.85B | +1 | −1 |
| Q3 2024 | 11 | -3 | 9.29M | $1.38B | n/a | −3 |
| Q2 2024 | 14 | n/a | 8.37M | $1.05B | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (pasivo) | 6.14M | +1.0% | $820.70M | 0.0% | ▲ Add | 2 | SEC ↗ ×18 |
| 2 | The Vanguard Group ✦ (pasivo) | 5.04M | -0.7% | $674.26M | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 3 | T. Rowe Price ✦ | 3.51M | -46.9% | $468.83M | 0.1% | ▼ Trim | 6 | SEC ↗ ×2 |
| 4 | Fidelity (FMR) ✦ | 2.69M | +66.8% | $359.73M | 0.0% | ▲ Add | 2 | SEC ↗ ×6 |
| 5 | State Street Global Advisors ✦ (pasivo) | 1.80M | +11.0% | $240.81M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 1.68M | +58.5% | $225.20M | 0.2% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Point72 Asset Management ✦ | 1.44M | -24.7% | $192.58M | 0.4% | ▼ Trim | 6 | SEC ↗ |
| 8 | Geode Capital Management ✦ (pasivo) | 1.03M | +5.3% | $138.03M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Millennium Management ✦ | 817.06K | +16.5% | $109.22M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 10 | JPMorgan Chase ✦ | 546.90K | n/a | $73.11M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 11 | Morgan Stanley ✦ | 484.98K | n/a | $64.83M | 0.0% | n/c | 1 | SEC ↗ ×15 |
| 12 | D. E. Shaw & Co. ✦ | 249.93K | +4337.7% | $33.41M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | PRIMECAP Management ✦ | 186.87K | +35.1% | $24.98M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | Marshall Wace ✦ | 181.06K | +115.0% | $24.20M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 15 | Goldman Sachs Group ✦ | 120.50K | n/a | $16.11M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 16 | Renaissance Technologies ✦ | 109.40K | +65.0% | $14.62M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 94.86K | -69.7% | $12.68M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 43.21K | +83.4% | $5.78M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 33.62K | Nuevo | $4.49M | 0.0% | New | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 9.22K | Nuevo | $1.18M | 0.0% | New | 1 | SEC ↗ ×3 |
| 21 | Adage Capital Partners ✦ | 5.00K | Nuevo | $668,350 | 0.0% | New | 1 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Bridgewater Associates | $4.49M | 0.0% |
| AQR Capital Management | $1.18M | 0.0% |
| Adage Capital Partners | $668,350 | 0.0% |
Posición cerrada
| Norges Bank | $30.99M | era 0.0% |
| Wellington Management | $17.85M | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 436 tenedores, 65.14M acciones, $6.86B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer, Director · 4.20K acc. · $798,380
Officer, Director · 1.33K acc. · $238,274
Officer, Director · 8.40K acc. · $1.60M
Officer, Director · 4.54K acc. · $862,980
Officer, Director · 5.43K acc. · $976,680
Officer, Director · 3.04K acc. · $503,506
Officer, Director · 5.43K acc. · $976,680
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología